Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non-cash Items (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Non-cash Items data on record, last reported at $43.0 million in Q4 2025.

  • For Q4 2025, Non-cash Items rose 1098.86% year-over-year to $43.0 million; the TTM value through Dec 2025 reached $43.0 million, up 1098.86%, while the annual FY2025 figure was $43.0 million, 1098.86% up from the prior year.
  • Non-cash Items reached $43.0 million in Q4 2025 per AMLX's latest filing, up from $5.1 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $201.8 million in Q4 2022 and bottomed at $1.8 million in Q1 2022.
  • Average Non-cash Items over 5 years is $30.7 million, with a median of $4.9 million recorded in 2025.
  • Peak YoY movement for Non-cash Items: soared 7092.7% in 2023, then crashed 96.28% in 2024.
  • A 5-year view of Non-cash Items shows it stood at $15.6 million in 2021, then surged by 1191.13% to $201.8 million in 2022, then plummeted by 86.3% to $27.6 million in 2023, then tumbled by 87.03% to $3.6 million in 2024, then skyrocketed by 1098.86% to $43.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $43.0 million in Q4 2025, $5.1 million in Q3 2025, and $4.9 million in Q2 2025.